Vaccinia immune globulin - DynPort Vaccine CompanyAlternative Names: VIGIV
Latest Information Update: 24 Jan 2006
$50 / €47 *
At a glance
- Originator DynPort Vaccine Company LLC
- Developer DynPort Vaccine Company
- Class Immunoglobulins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Smallpox
Most Recent Events
- 31 Dec 2005 Launched for Smallpox in USA (IV)
- 22 Feb 2005 Drug "Vaccinia immune globulin - DynPort Vaccine Company" has received Orphan Drug Status for Indication "Smallpox" in USA.
- 18 Feb 2005 Registered for Smallpox in USA (IV)